#NDMM

BENEFIT: Isa-VRd Improves MRD in Transplant-Ineligible Newly Diagnosed Multiple Myeloma - Hematology Advisor Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.

3 months ago

For patients with transplant-ineligible, #NDMM, treatment with the Isa-VRd quadruplet regimen induced sustained MRD negativity rates in an analysis of the BENEFIT trial. Arthur Bobin, MD of @chu-poitiers.bsky.social presented at #ASH25, by @cancertherapyadv.bsky.social.

https://bit.ly/3MveTLH

1 0 0 0

@cancertherapyadv.bsky.social

3 months ago

KRd significantly prolonged PFS and improved the MRD negativity rate compared to VRd in newly diagnosed #multipleMyeloma. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.

Read more here: ➡️ https://bit.ly/48NmWe6

#NDMM

0 0 0 0

Cancer Therapy Advisor

3 months ago

BENEFIT: Isa-VRd Improves MRD in Transplant-Ineligible Newly Diagnosed Multiple Myeloma The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

For patients with transplant-ineligible, newly- diagnosed #multipleMyeloma, treatment with the Isa-VRd quadruplet regimen induced sustained MRD negativity rates in an analysis of the BENEFIT trial. Presented by Arthur Bobin, MD of @chu-poitiers.bsky.social at #ASH25.

https://bit.ly/4a3NtGt

#NDMM

1 0 0 0

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM Larry Anderson, MD discusses the results from the AURIGA study comparing subcutaneous daratumumab to lenalidomide in patients with NDMM.

4 months ago

Dr. Anderson of UT Southwestern Medical Center in Dallas, Texas, and the lead clinical investigator for the AURIGA study, sat down with us at #IMS2025 to provide more in-depth information on this study and its clinical significance.

https://bit.ly/4hSsrMT

#NDMM #MultipleMyeloma

0 0 0 0

CTCs Show Promise as Prognostic Biomarker in Newly Diagnosed Multiple Myeloma CTC levels may be prognostic in patients with transplant-eligible, newly diagnosed MM who were treated with a standard-of-care quadruplet regimen.

4 months ago

CTC levels are an independent prognostic factor for patients with transplant-eligible, #NDMM who were treated with a standard-of-care quadruplet regimen. Published in @bloodjournals.hematology.org and @cancertherapyadv.bsky.social.

https://bit.ly/4oHqTYd

#multipleMyeloma

0 0 0 0

5 months ago

14/Unfortunately, pts w high-risk (HR) #NDMM have 👎poorer prognosis & shorter survival rates vs standard-risk

0 1 1 0

5 months ago

11/Do results w isa show similar trends?

IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM

👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts

2 1 1 0

5 months ago

9/CEPHEUS compared induction/consolidation w VRd ± daratumumab (D) followed by maintenance in transplant-ineligible (TIE) #NDMM

The DVRd arm demonstrated which of the following outcomes?

💬 REPLY👇

1️⃣ Deep, more durable MRD-
2️⃣ ⬆️MRD- rates. No🔺in PFS
3️⃣ Similar efficacy, ⬆️VTE
4️⃣ ⬆️ D/C rate in DVRd arm

0 1 1 0

5 months ago

8/🔬Exciting news for #mmsm
Quad tx as🆕SOC for #NDMM

Current EHA-EMN (1st optn) & NCCN (pref,cat 1) regimens for TE pts w/NDMM:
🎯DaraVRd➡️SCT➡️len maint
🎯IsaVRd SCT➡️len maint

👏to quad as 1L for TE pts👏
…but what about pts who are TIE /SCT-deferred?

0 1 1 0

5 months ago

3/🥼In your practice, which regimen are you using most often for 1L therapy in pts w/ transplant eligible (TE) #NDMM?

☎️ #MedSky #HemeSky 💬 reply and let us know what you do in your practice?

1️⃣ DVRd quad
2️⃣ IsaVRd quad
3️⃣ DKRd or IsaKRd quad
4️⃣ VRd
5️⃣ other triplet

0 1 1 0